SHS invests in Simulands AG
The German life science and medtech investor SHS Gesellschaft für Beteiligungsmanagement mbH has made a EUR 10 million investment in Simulands AG, a Zurich-based manufacturer of simulation devices for medical training of cardiovascular interventions.
A fund advised by AFINUM Management AG buys GS Swiss PCB
A fund advised by AFINUM Management AG signed on 8 October 2021 a share purchase agreement with exceet Group AG, a company of the exceet Group, to buy exceet Group's portfolio company GS Swiss PCB AG.
CombiGene and Spark enter global licensing agreement for gene therapy
STOCKHOLM - CombiGene AB and Spark Therapeutics announced the signing of an exclusive collaboration and licensing agreement for CombiGene’s CG01 project.
evitria Group sold to Atlas Antibodies, Sweden
The shareholders of the evitria Group have sold the evitria Group to Atlas Antibodies, Sweden. The transaction was completed on August 5, 2021.
Global Development Alliance between Numab Therapeutics and Kaken Pharmaceutical
On January 13, 2021, Numab Therapeutics AG (Wädenswil, Switzerland) entered into a global co-development and regional licensing agreement with Kaken Pharmaceutical Co., Ltd. (Tokyo, Japan) for Numab's novel multispecific anti-inflammatory drug candidate NM26- 2198, which blocks three key pathways in the pathophysiology of atopic dermatitis.
MCAM Symalit acquires Recycling Activities from Minger Kunststofftechnik
MCAM Symalit AG, Lenzburg, a group company of the Mitsubishi Chemical Advanced Materials group, a leading global manufacturer of high-performance materials, takes over all Recycling related activities and assets, current...
Numab and Sunshine Guojian form partnership
3SBio Inc.’s subsidiary Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (“Sunshine Guojian”) and Numab have formed a partnership focusing on the development and commercialization of a portfolio of novel multi-specific...
NUMAB concludes Licensing and Development Agreement in China
Suzhou, China and Pfäffikon SZ, Switzerland May 2, 2019 – CStone Pharmaceuticals ("CStone"; HKEX: 2616) and Numab Therapeutics AG ("Numab") have entered into an exclusive regional licensing agreement for the development and...
AFINUM acquires majority stake in evitria AG
AFINUM Achte Beteiligungsgesellschaft mbH & Co. KG acquired a majority stake in the Schlieren (Switzerland) based biotech company evitria AG from its founder. evitria AG is one of the leading providers of custom antibodies for...
US / Swiss health solution provider group acquires Swiss pharmacy
A US / Swiss health solution provider group based in Geneva and Pennsilvania acquired a Swiss pharmacy from its founder. VISCHER acted as transaction counsel to the buyer.
The VISCHER team was led by Felix W. Egli and further...